Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by retiredcfon Sep 01, 2024 6:52am
125 Views
Post# 36204445

RE:Keystone Financial

RE:Keystone FinancialHere's the revised ad. GLTA

As we celebrate labour day this weekend, we look back at the unknown, high-quality earnings Small-Cap stock recommended one year ago to this date. 

That company, Cipher Pharmaceuticals (CPH:TSX) is now the best performing stock on the entire Toronto Stock Exchange over the past year, up 388.17%.

Do not miss out on our last 10x Stock Webinar this coming week – where we profile 5-6 new small-cap stock buy recommendations. 
September 5th @ 4:00 PM Pacific / 7:00 PM Eastern. The event is 86% sold out.

CLICK HERE FOR MORE INFORMATION

If you attended KeyStone’s Fall 2023 Live Webinars and became a client to our Small-Cap Research, below we provide Quick Updates on the first two Canadian Small-Cap Recommendations new clients received following the event.

Quick Update:

Cipher Pharmaceuticals (CPH:TSX)

Recommended: August 28, 2023, at $3.89

Today’s Price: $18.99

Gain: 388.17%

Cipher (CPH:TSX) is a unique specialty pharmaceutical Small-Cap Stock that is profitable, growing organically & via acquisitions, with a strong cash rich (originally 45%+ of its value in cash & no debt) balance sheet. The stock recently made a transformational acquisition and continues to report solid financial results driving it to new highs. Cipher is a recent excellent example of how research can produce strong gains for clients.

Cipher has now gained over 388% in less than one year. The huge gains are not driven by hype but powered by strong earnings and a transformational acquisition made primarily from cash on hand without diluting existing shareholders.

Quick Update:

VitalHub (VHI:TSX)

Recommended: November 2023, at $3.24

Today’s Price: $8.02

Gain: 147.53%

KeyStone’s second Small-Cap BUY recommendation to clients following our 2023 Webinars, was VitalHub (VHI:TSX), a small-cap Canadian healthcare software company, at a price of $3.24. We had followed VitalHub and interviewed management for years, but were monitoring the stock for an attractive entry point. Just 9 months after our initial recommendation the stock rose 147.53% to $8.02, driven by strong cash flow generation, a significant acquisition and a cash rich balance sheet.

Do not miss out on the next Cipher or VitalHub.


<< Previous
Bullboard Posts
Next >>